CN107115384A - Pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect and its preparation method and application - Google Patents

Pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect and its preparation method and application Download PDF

Info

Publication number
CN107115384A
CN107115384A CN201710385574.9A CN201710385574A CN107115384A CN 107115384 A CN107115384 A CN 107115384A CN 201710385574 A CN201710385574 A CN 201710385574A CN 107115384 A CN107115384 A CN 107115384A
Authority
CN
China
Prior art keywords
extract
polygala
pharmaceutical composition
obtains
balloonflower root
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710385574.9A
Other languages
Chinese (zh)
Inventor
徐金城
张军龙
吕卓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NINGXIA GOLD SUN PHARMACEUTICAL CO Ltd
Original Assignee
NINGXIA GOLD SUN PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NINGXIA GOLD SUN PHARMACEUTICAL CO Ltd filed Critical NINGXIA GOLD SUN PHARMACEUTICAL CO Ltd
Priority to CN201710385574.9A priority Critical patent/CN107115384A/en
Publication of CN107115384A publication Critical patent/CN107115384A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/69—Polygalaceae (Milkwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Abstract

The invention discloses a kind of pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect and its preparation method and application, the pharmaceutical composition is made up of Radix Platycodonis extract and milkwort extract, wherein Radix Platycodonis extract is 15 100 parts by weight, and milkwort extract is 10 75 parts by weight.Pharmaceutical composition of the present invention has effects that cough-relieving apophlegmatic is relievingd asthma, and therapeutic effect is good, persistent；Have no toxic side effect；Simple production process, balloonflower root, polygala are conventional Chinese medicine, and dose is low, and production cost is low.

Description

Pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect and its preparation method and application
Technical field
The present invention relates to pharmaceutical field, more particularly, to a kind of pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect And preparation method thereof.
Background technology
Respiratory disease be endanger our people health common disease and frequently-occurring disease, such as the infection of the upper respiratory tract, tracheitis, Bronchial astehma, chronic bronchitis, chronic obstructive pneumonia, Influenza A H1N1 etc..In recent years, due to the aging of society And the aggravation of environmental pollution, the incidence of disease of respiratory disease also constantly rising.Cough, breathe heavily, phlegm is respiratory disease Main clinical symptoms, both can individually occur, and can also exist simultaneously, and can influence each other.
Therefore provide a kind of while the pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect is very necessary.
The content of the invention
It is an object of the invention to provide a kind of while having the pharmaceutical composition of antiasthmatic-antitussive eliminating the phlegm effect.
There is the preparation side of the pharmaceutical composition of antiasthmatic-antitussive eliminating the phlegm effect simultaneously it is a further object of the present invention to provide this Method.
The purpose of the present invention is achieved in the following ways：
A kind of pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect, the pharmaceutical composition is carried by Radix Platycodonis extract and polygala Thing is taken to constitute, wherein Radix Platycodonis extract is 15-100 parts by weight, milkwort extract is 10-75 parts by weight.
The above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect, preferably Radix Platycodonis extract are 20-80 parts by weight, polygala Extract is 10-70 parts by weight.
The above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect, further preferred Radix Platycodonis extract is 20-30 weight Part, milkwort extract is 15-20 parts by weight
The above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect, more excellent Radix Platycodonis extract is 30 parts by weight, polygala Extract is 20 parts by weight.
The above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect, Radix Platycodonis extract is to be prepared by the following method to obtain 's：Balloonflower root is through CO2Supercritical extract obtains balloonflower root extract and the balloonflower root dregs of a decoction, by balloonflower root extract beta-cyclodextrin inclusion compound, Obtain inclusion compound；Balloonflower root dregs of a decoction alcohol extracting, filtering obtains filtrate, and filtrate concentration obtains alcohol-extracted extract；By above-mentioned inclusion compound and alcohol Extracted extract is mixed, and obtains Radix Platycodonis extract.
The above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect, milkwort extract is to be prepared by the following method to obtain 's：Polygala is through CO2Supercritical extract obtains polygala extract and the polygala dregs of a decoction, by polygala extract beta-cyclodextrin inclusion compound, Obtain inclusion compound；Polygala dregs of a decoction alcohol extracting, filtering obtains filtrate, and filtrate concentration obtains alcohol-extracted extract；By above-mentioned inclusion compound and alcohol Extracted extract is mixed, and obtains milkwort extract.
Balloonflower root used in the present invention is Campanulaceae balloonflower root Platycodon grandiflorum (Jacq.) A.Dc.'s Dry root.Major function：Facilitaing lung, relieving sore-throat, eliminating the phlegm, apocenosis.Polygala is milk wort polygala Polygala tenuifolia Willd. or ovum leaf polygala Polygala sibirica L. dry root.Major function：Tranquilize the mind and promote the intelligence, restoring normal coordination between heart and kidney, eliminating the phlegm, Detumescence.
Preparation is made with pharmaceutically acceptable auxiliary material in the above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect.
Following formulation is made in the above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect：Tablet, granule, capsule, Pill.
The preparation method of the above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect comprises the following steps：
(1) balloonflower root is through CO2Supercritical extract obtains balloonflower root extract and the balloonflower root dregs of a decoction, and balloonflower root extract is pasted with β-ring Spermatophore is closed, and obtains inclusion compound；Balloonflower root dregs of a decoction alcohol extracting, filtering obtains filtrate, and filtrate concentration obtains alcohol-extracted extract；By above-mentioned inclusion Thing and alcohol-extracted extract mixing, obtain Radix Platycodonis extract；
(2) polygala is through CO2Supercritical extract obtains polygala extract and the polygala dregs of a decoction, and polygala extract is pasted with β-ring Spermatophore is closed, and obtains inclusion compound；Polygala dregs of a decoction alcohol extracting, filtering obtains filtrate, and filtrate concentration obtains alcohol-extracted extract；By above-mentioned inclusion Thing and alcohol-extracted extract mixing, obtain milkwort extract；
(3) Radix Platycodonis extract is proportionally mixed with milkwort extract, produced.
The preparation method of the above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect, the CO described in step (1)2It is overcritical Extraction conditions is：Extracting pressure is 25-35MPa, 30-45 DEG C of extraction temperature, CO2Flow 20-35L/h, extraction time 1-2h；Tangerine Stalk extract carries out inclusion condition with beta-schardinger dextrin and is：Ratio between balloonflower root extract and beta-schardinger dextrin is 1ml：4-6g, plus Water is measured as 4-8 times again, and the inclusion time is 15-45 minutes；Balloonflower root dregs of a decoction alcohol extracting condition is：Plus 6-10 times of weight of the balloonflower root dregs of a decoction 60%-90% ethanol heating and refluxing extraction 1-3 times, each 1-2 hours, phegma stands more than 12 hours, Aspirate supernatant, filter Cross, obtain filtrate；Filtrate is concentrated under reduced pressure into relative density 1.1-1.3 alcohol-extracted extract under the conditions of 60 DEG C.
It is preferred that step (1) described in CO2Supercritical extract condition is：Extracting pressure is 30-35MPa, extraction temperature 35- 45 DEG C, CO2Flow 25-35L/h, extraction time 1-1.5h；Balloonflower root extract carries out inclusion condition with beta-schardinger dextrin：Balloonflower root extracts It is 1ml to take the ratio between thing and beta-schardinger dextrin：4-5g, times amount that adds water is 6-8 times, and the inclusion time is 15-30 minutes；Balloonflower root medicine Slag alcohol extracting condition is：Plus 8-10 times of balloonflower root dregs of a decoction weight 70-90% ethanol heating and refluxing extraction 2-3 times, it is each 1.5-2 hours, Phegma stands more than 12 hours, Aspirate supernatant, filtration, obtains the dregs of a decoction and filtrate；Filtrate is concentrated under reduced pressure under the conditions of 60 DEG C To relative density 1.15-1.25 alcohol-extracted extract.
The preparation method of the above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect, the polygala CO described in step (2)2It is super Critical extraction conditions is：Extracting pressure is 25-35MPa, 30-45 DEG C of extraction temperature, CO2Flow 20-35L/h, extraction time 1- 2h；Polygala extract carries out inclusion condition with beta-schardinger dextrin：Ratio between polygala extract and beta-schardinger dextrin is 1ml：4- 6g, times amount that adds water is 4-8 times, and the inclusion time is 15-45 minutes；Polygala dregs of a decoction alcohol extracting condition is：Plus 6-10 times of the polygala dregs of a decoction are weighed Measure 60%-90% ethanol heating and refluxing extraction 1-3 times, each 1-2 hours, phegma stands more than 12 hours, Aspirate supernatant, Filtration, obtains the dregs of a decoction and filtrate；Filtrate is concentrated under reduced pressure into relative density 1.1-1.3 alcohol-extracted extract under the conditions of 60 DEG C.
It is preferred that step (2) described in polygala CO2Supercritical extract condition is：Extracting pressure is 30-35MPa, extraction temperature 35-45 DEG C of degree, CO2Flow 25-35L/h, extraction time 1-1.5h；Described polygala extract carries out inclusion bar with beta-schardinger dextrin Part is：Ratio between polygala extract and beta-schardinger dextrin is 1ml：4-5g, times amount that adds water is 6-8 times, and the inclusion time is 15-30 Minute；Polygala dregs of a decoction alcohol extracting condition is：Plus 8-10 times of polygala dregs of a decoction weight 70%-90% ethanol heating and refluxing extraction 2-3 times, often Secondary 1.5-2 hours, phegma stands more than 12 hours, Aspirate supernatant, and filtration obtains the dregs of a decoction and filtrate；Filtrate is in 60 DEG C of bars Relative density 1.15-1.25 alcohol-extracted extract is concentrated under reduced pressure under part.
The above-mentioned pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect is in treatment cough, expectoration, asthma due to excessive phlegm medicine is prepared Application.
Beneficial effects of the present invention compared with the prior art：Pharmaceutical composition of the present invention has the work(of antiasthmatic-antitussive eliminating the phlegm Effect, therapeutic effect is good, persistent；Have no toxic side effect；Simple production process, balloonflower root, polygala are conventional Chinese medicine, and dose is low, Production cost is low.
Embodiment
The present invention is further detailed below by way of specific test example.
Embodiment 1
The pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect of the present embodiment production, is extracted by Radix Platycodonis extract and polygala Thing is constituted.
The preparation of the pharmaceutical composition is followed the steps below：
(1) balloonflower root utilizes CO2Supercritical extraction is extracted, and extracting pressure is 30MPa, 35 DEG C of extraction temperature, CO2Stream 25L/h, extraction time 1.5h are measured, balloonflower root extract and the balloonflower root dregs of a decoction are obtained, extract is included with beta-schardinger dextrin, extracted Ratio between thing and beta-schardinger dextrin is 1ml：4g, times amount that adds water is 6 times, bag and 25 minutes time, obtains inclusion compound；Balloonflower root medicine Slag adds 8 times of 70% ethanol heating and refluxing extractions of weight 3 times, 1.5 hours every time, and phegma stands more than 12 hours, draws supernatant Liquid, filtration, obtains the dregs of a decoction and filtrate；Filtrate is concentrated under reduced pressure into relative density 1.15-1.25 alcohol-extracted extract under the conditions of 60 DEG C； Above-mentioned inclusion compound and alcohol-extracted extract are mixed, Radix Platycodonis extract is obtained；
(2) polygala utilizes CO2Supercritical extraction is extracted, and extracting pressure is 30MPa, 35 DEG C of extraction temperature, CO2Stream 25L/h, extraction time 1.5h are measured, polygala extract, and the polygala dregs of a decoction are obtained, extract is included with beta-schardinger dextrin, extracted It is 1ml to take the ratio between thing and beta-schardinger dextrin：4g, times amount that adds water is 6 times, bag and 25 minutes time, obtains inclusion compound.Polygala The dregs of a decoction add 8 times of 70% ethanol heating and refluxing extractions of weight 3 times, 1.5 hours every time, and phegma stands more than 12 hours, in absorption Clear liquid, filtration, obtains the dregs of a decoction and filtrate；Filtrate is concentrated under reduced pressure into relative density 1.15-1.25 alcohol extracting leaching under the conditions of 60 DEG C Cream；Above-mentioned inclusion compound and alcohol-extracted extract are mixed, milkwort extract is obtained；
(3) parts by weight of Radix Platycodonis extract 30 are mixed with the parts by weight of milkwort extract 20, produced.
Embodiment 2
The pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect of the present embodiment production, is extracted by Radix Platycodonis extract and polygala Thing is constituted.
The preparation of the pharmaceutical composition is followed the steps below：
(1) balloonflower root utilizes CO2Supercritical extraction is extracted, and extracting pressure is 35MPa, 40 DEG C of extraction temperature, CO2Stream 30L/h, extraction time 2h are measured, balloonflower root extract, and the balloonflower root dregs of a decoction are obtained, extract is included with beta-schardinger dextrin, extracted Ratio between thing and beta-schardinger dextrin is 1ml：5g, times amount that adds water is 8 times, bag and 30 minutes time, obtains inclusion compound；Balloonflower root medicine Slag adds 8 times of 90% ethanol heating and refluxing extractions of weight 3 times, 1.5 hours every time, and phegma stands more than 12 hours, draws supernatant Liquid, filtration, obtains the dregs of a decoction and filtrate；Filtrate is concentrated under reduced pressure into relative density 1.15-1.25 alcohol-extracted extract under the conditions of 60 DEG C； Above-mentioned inclusion compound and alcohol-extracted extract are mixed, Radix Platycodonis extract is obtained；
(2) polygala utilizes CO2Supercritical extraction is extracted, and extracting pressure is 35MPa, 40 DEG C of extraction temperature, CO2Stream 30L/h, extraction time 2h are measured, polygala extract, and the polygala dregs of a decoction are obtained, extract is included with beta-schardinger dextrin, extracted Ratio between thing and beta-schardinger dextrin is 1ml：5g, times amount that adds water is 8 times, bag and 30 minutes time, obtains inclusion compound；Polygala medicine Slag adds 8 times of 90% ethanol heating and refluxing extractions of weight 3 times, 1.5 hours every time, and phegma stands more than 12 hours, draws supernatant Liquid, filtration, obtains the dregs of a decoction and filtrate；Filtrate is concentrated under reduced pressure into relative density 1.15-1.25 alcohol-extracted extract under the conditions of 60 DEG C； Above-mentioned inclusion compound and alcohol-extracted extract are mixed, milkwort extract is obtained；
(3) parts by weight of Radix Platycodonis extract 90 are mixed with the parts by weight of milkwort extract 70, produced.
Comparative example：Balloonflower root 150g is taken to be ground into fine powder, it is standby；Coarse powder is added water to cook three times, first and second time with polygala 100g Each 1.5 hours, third time 1 hour, collecting decoction, filtration, it is 1.32-1.35's (65 DEG C) that filtrate decompression, which is concentrated into relative density, Thick paste, adds balloonflower root fine powder, and mixing is produced.
Effect experiment
Test antitussive action experiment
1. animal：Mouse, male and female half and half, 18~22g of body weight,.
2. medicine：Pharmaceutical composition (being prepared according to the method for embodiment 1) of the present invention.
3. comparative example：Prepared by prior art.
Method and result
1. ammoniacal liquor causes mouse cough experiment
1.1 packet：Mouse is randomly divided into 4 groups：Blank control group (waits appearance physiological saline group), aspirin group (0.1g/ Kg), pharmaceutical composition group (0.033g crude drugs/kg), four dosage groups of comparative example group (0.033g crude drugs/kg).
1.2 experimental method：Mouse is taken to be grouped at random, daily gastric infusion each 1 time sooner or later, successive administration 5 days is given on the 5th day 1h after medicine, mouse is placed in experimental box, and 25~28% ammoniacal liquor 20s are sprayed into experimental box, and record self-spray rises small in 5min Mouse incubation period and cough number of times.
1.3 result：Pharmaceutical composition group, comparative example group and positive drug aspirin group can significantly reduce ammoniacal liquor and cause mouse Cough number of times in 5min, extends cough latent period, has conspicuousness (P with blank control group comparing difference<0.05 or P< 0.01, it is shown in Table 1).
The shadow that the pharmaceutical composition of table 1. is coughed to ammonia spraying induced mice
Note：Compared with blank control group, * P<0.05；**P<0.01
Pharmaceutical composition group can reduce the cough number of times that ammoniacal liquor causes mouse cough model, equal to each administration group of cough latent period There is extension effect, have conspicuousness with blank control group comparing difference.Point out the pharmaceutical composition that there is good antitussive action, with Comparative example group compares, and has conspicuousness progress.
Test the experiment of two resolve phlegm effects
1. animal：Mouse, male and female half and half, 18~22g of body weight.
2. medicine：Pharmaceutical composition (being prepared according to the method for embodiment 1) of the present invention.
3. comparative example：Prepared by prior art.
Method and result
1. the influence of the phenol red expectoration amount of pair mouse tracheae：
1.1 packet：Mouse is randomly divided into 4 groups：Blank control group (isometric(al) physiological saline), ammonium chloride group (1.0g/kg), Pharmaceutical composition group (0.033g crude drugs/kg), four dosage groups of comparative example group (0.033g crude drugs/kg).
1.2 experimental method：Mouse is taken to be grouped at random, daily gastric infusion each 1 time sooner or later, continuous 5 days, after administration in the 5th day 1h, mouse is put to death after 5% phenol red (0.1ml/10g body weight), 30min is injected intraperitoneally.Mouse is cut from thyroid cartilage to tracheorrhaphy One section of tracheae at branch, is put into the test tube for filling 2ml physiological saline, shaking, 0.1ml1mol/LNaOH is added, with 754 points Light photometer (Shanghai) surveys OD values under the conditions of wavelength 550nm.The phenol red discharge of tracheae that every mouse is found according to phenol red standard curve Amount.
1.3 experimental result：Pharmaceutical composition group, comparative example group, positive drug ammonium chloride group can substantially increase mouse tracheae Phenol red discharge rate, has conspicuousness (P with blank control group comparing difference<0.05 or P<0.01) (2 are shown in Table).
Influence of the pharmaceutical composition of table 2. to the phenol red expectoration amount of mouse tracheae
Note：Compared * P with blank control group<0.05；**P<0.01
Pharmaceutical composition can increase the liquid column length that capillary draws tracheal secretion.Point out the pharmaceutical composition that there is change Phlegm is acted on, and has certain help to improving symptom, being compared with comparative example group has marked improvement.
Test the experiment of three antiasthmatic effects
1. animal：Cavy, male and female half and half, 180~200g of body weight.
2. medicine：Pharmaceutical composition (being prepared according to the method for embodiment 1) of the present invention.
3. comparative example：Prepared by prior art.
Method and result
1. influence of the pharmaceutical composition to Experimental Asthma In Guinea-pigs
1.1 packet：Cavy is randomly divided into following 4 groups：Blank control group (isometric(al) physiological saline), positive drug aminophylline group (0.025g/kg), pharmaceutical composition group (0.039g crude drugs/kg), four dosage groups of comparative example group (0.039g crude drugs/kg).
1.2 method：Take cavy to be grouped at random, daily gastric infusion each 1 time sooner or later, continuous 5 days, the 5th day in after administration 1h, Cavy is placed in experimental box, 2% acecoline of atomization is sprayed into experimental box and 0.1% histamine phosphate's isometric(al) is mixed Close liquid 15s, asthmatic latent period after record administration.
1.3 result：Pharmaceutical composition, comparative example group and positive drug aminophylline group can be obviously prolonged drawing for cavy and breathe heavily latent Phase, there is conspicuousness (P with blank control group comparing difference<0.05 or P<0.01) (3 are shown in Table).
Influence of the pharmaceutical composition of table 3. to Experimental Asthma In Guinea-pigs
Note：Compared with blank control group, * P<0.05；**P<0.01；
Pharmaceutical composition can be obviously prolonged acecoline plus histamine phosphate causes the asthmatic latent period of cavy, and pointing out should Pharmaceutical composition may have antiasthmatic effect, and being compared with comparative example group has marked improvement.
Test the experiment of four antiinflammatory actions
1. animal：KM mouse, male and female half and half, 18~22g of body weight.
2. medicine：Pharmaceutical composition (being prepared according to the method for embodiment 1) of the present invention.
3. comparative example：Prepared by prior art.
Method and result
1. the influence of pharmaceutical composition paraxylene induced mice auricle edema
1.1 packet：In the lab by Mouse feeder one day to adapt to environment, then sub-cage rearing, is randomly divided into following 4 Group：Blank control group (isometric(al) physiological saline), positive drug indocin group (0.01625g/kg), pharmaceutical composition group (0.033g Crude drug/kg), four dosage groups of comparative example group (0.033g crude drugs/kg).
1.2 method：Take mouse to be grouped at random, daily gastric infusion each 1 time sooner or later, continuous 5 days, the 5th day in after administration 1h, Dimethylbenzene is applied to two sides before and after mouse right ear, per mouse 0.08ml, left ear is compared.Animal is put to death after 1h, is punched with 9mm diameters Device lays round auricle at same position respectively, uses scales/electronic balance weighing.Mice auricle swelling rate is calculated according to formula.
Swelling rate (100%)=(auris dextra weight-left ear weight)/left ear weight × 100%
Swelling inhibiting rate %=(control group swelling rate-administration group swelling rate)/control group swelling rate × 100%
1.3 result：Pharmaceutical composition group, comparative example group and positive drug indocin group, which have, substantially suppresses dimethylbenzene induced mice The effect of auricle edema, has conspicuousness (being shown in Table 4) with blank control group comparing difference.
The influence of the pharmaceutical composition paraxylene induced mice auricle edema rate of table 4.
Note：Compared with blank control group, * P<0.05；**P<0.01.
Pharmaceutical composition group, comparative example group and positive drug indocin group have different degrees of to chmice acute inflammatory model The increase of anti-inflammatory early stage capillary permeability, Inflammatory substances can be oozed out and tissue edema, point out the medicine by antagonism Composition may have preventive and therapeutic effect to acute inflammation, and being compared with comparative example group has marked improvement.
Clinical test
1. case selection standard
Primary symptom：Coughing with a lot of sputum, shortness of breath is panted
Secondary disease：Pharynx is itched or pain, uncomfortable in chest, and it is unfavorable to breathe, nasal obstruction, runny nose, fever with aversion to cold
Possess above primary symptom one, secondary disease 2, the age is in 18-60 year persons, you can.
2. therapeutic scheme
Administrated method：It is 0.25g/ pieces that the pharmaceutical composition prepared by embodiment 1, which adds appropriate amount of auxiliary materials to be made containing crude drug amount, Tablet, piece weight 0.28g, for clinical test.Orally, one at a time, 2 times a day.The course for the treatment of：Medication 5 days.
3. curative effect determinate standard
Recovery from illness：Observed clinical symptoms, sign disappear or basic disappearance, and disease total mark curative effect is more than 95%；
It is effective：Observed clinical symptoms, sign are obviously improved, and disease total mark curative effect is between 70%-95%；
Effectively：Observed clinical symptoms, sign take a favorable turn, and disease total mark curative effect is between 30%-70%；
It is invalid：Observed clinical symptoms, sign, which have no, to be obviously improved, or is aggravated on the contrary, and disease total mark curative effect is 30% Below.
Curative effect calculation formula：Integration * 100% before curative effect=(being integrated before treatment after integration-treatment)/treatment
4. efficacy result
The efficacy result table of table 5.
Note：300 cases do not occur any vomiting phenomenon in medication cycle.

Claims (10)

1. a kind of pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect, it is characterised in that the pharmaceutical composition is extracted by balloonflower root Thing and milkwort extract composition, wherein Radix Platycodonis extract are 15-100 parts by weight, and milkwort extract is 10-75 parts by weight.
2. the pharmaceutical composition according to claim 1 with antiasthmatic-antitussive eliminating the phlegm effect, it is characterised in that the medicine group Compound is made up of Radix Platycodonis extract and milkwort extract, and wherein Radix Platycodonis extract is 20-80 parts by weight, and milkwort extract is 10- 70 parts by weight.
3. the pharmaceutical composition according to claim 1 or 2 with antiasthmatic-antitussive eliminating the phlegm effect, it is characterised in that described Radix Platycodonis extract, which is prepared by the following method, to be obtained：Balloonflower root is through CO2Supercritical extract obtains balloonflower root extract and balloonflower root The dregs of a decoction, by balloonflower root extract beta-cyclodextrin inclusion compound, obtain inclusion compound；Balloonflower root dregs of a decoction alcohol extracting, filtering, obtains filtrate, filtrate is dense Contracting, obtains alcohol-extracted extract；Above-mentioned inclusion compound and alcohol-extracted extract are mixed, Radix Platycodonis extract is obtained.
4. the pharmaceutical composition according to claim 1 or 2 with antiasthmatic-antitussive eliminating the phlegm effect, it is characterised in that described Milkwort extract, which is prepared by the following method, to be obtained：Polygala is through CO2Supercritical extract obtains polygala extract and polygala The dregs of a decoction, by polygala extract beta-cyclodextrin inclusion compound, obtain inclusion compound；Polygala dregs of a decoction alcohol extracting, filtering, obtains filtrate, filtrate is dense Contracting, obtains alcohol-extracted extract；Above-mentioned inclusion compound and alcohol-extracted extract are mixed, milkwort extract is obtained.
5. the pharmaceutical composition according to claim 1 or 2 with antiasthmatic-antitussive eliminating the phlegm effect, it is characterised in that the medicine Preparation is made with pharmaceutically acceptable auxiliary material in composition.
6. the pharmaceutical composition according to claim 5 with antiasthmatic-antitussive eliminating the phlegm effect, it is characterised in that the medicine group Following formulation is made in compound：Tablet, granule, capsule, pill.
7. a kind of preparation method of the pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect described in claim 1 or 2, its feature It is that this method comprises the following steps：
(1) balloonflower root is through CO2Supercritical extract obtains balloonflower root extract and the balloonflower root dregs of a decoction, by balloonflower root extract beta-schardinger dextrin bag Close, obtain inclusion compound；Balloonflower root dregs of a decoction alcohol extracting, filtering obtains filtrate, and filtrate concentration obtains alcohol-extracted extract；By above-mentioned inclusion compound and Alcohol-extracted extract is mixed, and obtains Radix Platycodonis extract；
(2) polygala is through CO2Supercritical extract obtains polygala extract and the polygala dregs of a decoction, by polygala extract beta-schardinger dextrin bag Close, obtain inclusion compound；Polygala dregs of a decoction alcohol extracting, filtering obtains filtrate, and filtrate concentration obtains alcohol-extracted extract；By above-mentioned inclusion compound and Alcohol-extracted extract is mixed, and obtains milkwort extract；
(3) Radix Platycodonis extract is proportionally mixed with milkwort extract, produced.
8. the preparation method of the pharmaceutical composition according to claim 7 with antiasthmatic-antitussive eliminating the phlegm effect, its feature exists In the CO described in step (1)2Supercritical extract condition is：Extracting pressure is 25-35MPa, 30-45 DEG C of extraction temperature, CO2Flow 20-35L/h, extraction time 1-2h；Described balloonflower root extract carries out inclusion condition with beta-schardinger dextrin：Balloonflower root extract and β- Ratio between cyclodextrin is 1ml：4-6g, times amount that adds water is 4-8 times, and the inclusion time is 15-45 minutes；The described balloonflower root dregs of a decoction Alcohol extracting condition is：Plus 6-10 times of balloonflower root dregs of a decoction weight 60%-90% ethanol heating and refluxing extraction 1-3 times, it is each 1-2 hours, return Flow liquid stands more than 12 hours, Aspirate supernatant, filtration, obtains filtrate；Filtrate is concentrated under reduced pressure into relatively close under the conditions of 60 DEG C Spend 1.1-1.3 alcohol-extracted extract.
9. the preparation method of the pharmaceutical composition according to claim 7 with antiasthmatic-antitussive eliminating the phlegm effect, its feature exists In the polygala CO described in step (2)2Supercritical extract condition is：Extracting pressure is 25-35MPa, 30-45 DEG C of extraction temperature, CO2 Flow 20-35L/h, extraction time 1-2h；Described polygala extract carries out inclusion condition with beta-schardinger dextrin：Polygala extract Ratio between beta-schardinger dextrin is 1ml：4-6g, times amount that adds water is 4-8 times, and the inclusion time is 15-45 minutes；Described polygala Dregs of a decoction alcohol extracting condition is：Plus 6-10 times of polygala dregs of a decoction weight 60%-90% ethanol heating and refluxing extraction 1-3 times, each 1-2 is small When, phegma stands more than 12 hours, Aspirate supernatant, filtration, obtains the dregs of a decoction and filtrate；Filtrate is depressurized dense under the conditions of 60 DEG C It is reduced to relative density 1.1-1.3 alcohol-extracted extract.
10. the pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect described in claim 1 or 2 prepare treatment cough, expectoration, Application in asthma due to excessive phlegm medicine.
CN201710385574.9A 2017-05-26 2017-05-26 Pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect and its preparation method and application Pending CN107115384A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710385574.9A CN107115384A (en) 2017-05-26 2017-05-26 Pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710385574.9A CN107115384A (en) 2017-05-26 2017-05-26 Pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect and its preparation method and application

Publications (1)

Publication Number Publication Date
CN107115384A true CN107115384A (en) 2017-09-01

Family

ID=59728535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710385574.9A Pending CN107115384A (en) 2017-05-26 2017-05-26 Pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect and its preparation method and application

Country Status (1)

Country Link
CN (1) CN107115384A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101033246A (en) * 2007-04-10 2007-09-12 山东理工大学 Method of extracting platycodin by supercritical carbon dioxide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101033246A (en) * 2007-04-10 2007-09-12 山东理工大学 Method of extracting platycodin by supercritical carbon dioxide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
张冰: "《临床中药学》", 30 September 2012, 中国中医药出版社 *
武荣芳等: "《中药方剂学》", 31 January 2013, 西安交通大学出版社 *
章俊如等: "远志超临界CO2 萃取工艺研究", 《安徽医药》 *

Similar Documents

Publication Publication Date Title
CN103768308B (en) A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof
WO2011063553A1 (en) Traditional chinese medicine for treating flu induced by flu virus including type a h1n1 virus
CN103169891B (en) Novel vitamin C yinqiao tablet
CN101322761B (en) Medicament for treating tracheitis and bronchitic and preparation thereof
CN103989695B (en) A kind of pharmaceutical composition and application thereof treating bronchial asthma
CN107115384A (en) Pharmaceutical composition with antiasthmatic-antitussive eliminating the phlegm effect and its preparation method and application
CN102526236B (en) Pharmaceutical formulation for treating influenza and preparation method thereof
CN107137465A (en) A kind of pharmaceutical composition of effect of being relievingd asthma with cough-relieving apophlegmatic and preparation method thereof
CN106619533A (en) Sucrose-free compound granules for treating cold and preparation method thereof
CN101708207B (en) Medicinal composition for expelling phlegm and inhibiting cough and preparation method thereof
CN107184664A (en) Pharmaceutical composition of effect of being relievingd asthma with cough-relieving apophlegmatic and preparation method thereof
CN103816281A (en) Traditional Chinese medicine composition for preventing and treating wind-heat common cold
CN1981859A (en) Chinese-medicinal extract with liver-clearing and phlegm-resolving functions and its production
CN106038795A (en) Scoparia dulcis volatile oil extracting method and cough-relieving and asthma-relieving applications of the volatile oil
CN101569714B (en) Traditional Chinese medicine compound for treating chronic pharyngitis and the preparation method thereof
CN103599440A (en) Traditional Chinese medicine combination containing mango leaf
CN103893527A (en) Traditional Chinese medicine composition for nourishing yin, clearing away lung-heat, clearing heat and relieving sore throat and preparation method thereof
CN103272130B (en) Preparation method of traditional Chinese medicine for treating chronic nasosinusitis by machine
CN106727987A (en) A kind of medicine for treating cough
CN101125156A (en) Method for preparing compound senecio cannabifolius less composition and medical application
CN103566029A (en) Pharmaceutical composition for treating respiratory diseases and preparation method and usage thereof
CN103372121B (en) Traditional Chinese medicine composition for treating tuberculosis and lung disease, and preparation method thereof
CN101322770A (en) Compound creat formulation for resisting infection
CN109223955A (en) A kind of cough-relieving chrysanthemum lozenge
CN106692698A (en) Bletilla striata cough-relieving granules and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170901